All PlansCoverageHigh impact
Intradiscal Procedures - (Effective Date - 2026-10-15) 7.01.112
Excellus BlueCross BlueShield·Orthopedics, Neurosurgery, Pain Management +1 more·Bone & Joints (Orthopedic)
Effective date
Oct 15, 2026
We identified it
Jul 16, 2026
Summary
Excellus BlueCross BlueShield has classified a comprehensive list of intradiscal procedures as investigational/not covered, effective October 15, 2026. This includes thermal techniques (IDET, nucleoplasty, biacuplasty), automated discectomy, endoscopic approaches, and intradiscal injections (PRP, stem cells, ozone, etc.). Billing teams must deny all claims for these procedures and update authorization workflows to reflect non-coverage.
Action Required
By October 15, 2026: Billing team must update billing system and prior authorization rules to deny all intradiscal procedure claims submitted on or after this date, including: annulo-nucleoplasty, cervical intradiscal radiofrequency lesioning, coblation percutaneous disc decompression, hydrodiscectomy, intradiscal biacuplasty, intradiscal electrothermal annuloplasty (IEA/IDET), nucleoplasty, automated percutaneous lumbar discectomy (APLD), percutaneous laser disc decompression (PLDD), percutaneous disc decompression (PDD/Mild), percutaneous intradiscal radiofrequency thermocoagulation (PIRFT), radiofrequency annuloplasty (RA), targeted disc decompression (TDD), and intradiscal injections (methylene blue, hyaluronate, ozone, oxygen/ozone, bone marrow concentrates, chymopapain, PRP, mesenchymal stem cell, glucocorticoids, hyaluronidase, growth factors). Providers must be notified that these procedures are investigational and not eligible for coverage under Excellus BlueCross BlueShield plans. Update encounter forms and EMR templates to block ordering of these procedures. Claims submitted for these procedures will be denied as investigational/not covered. Providers should document this denial reason in patient records.